☆ 4.5 Article

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

TRANSLATIONAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Hui Wang et al.

Summary: We report a prevalence of approximately 0.7% for NTRK-positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors. NTRK gene fusions frequently co-occur with APC and TP53 aberrations, while they are almost always mutually exclusive with RAS/BRAF oncogenic alterations. NTRK-driven CRC patients show increased TMB, high microsatellite instability, and an enrichment for POLE/POLD1 mutations when compared to the molecularly unstratified CRC population.

CANCER MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

An integrative pan cancer analysis of RET aberrations and their potential clinical implications

Lei Zhou et al.

Summary: This study provides a comprehensive genomic analysis of RET aberrations in different cancer types and investigates their expression and clinical significance. RET abnormalities were found to be common in diverse cancers, with variations between different types. Co-occurring abnormalities and pathways associated with RET aberrations were identified, and the efficacy of FDA-approved RET-targeted therapies was evaluated. The findings of this study have important implications for the development of targeted therapies for RET abnormalities.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Article Oncology

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah et al.

Summary: This study investigated the efficacy and safety of Selpercatinib in patients with RET fusion-positive non-lung or thyroid advanced solid tumors. The results showed that Selpercatinib demonstrated clinically meaningful activity in the RET fusion-positive tumor-agnostic population, with a safety profile consistent with other indications.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Diana Bradford et al.

Summary: The FDA granted accelerated approval to selpercatinib on May 8, 2020 for patients with metastatic RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The approval was based on significant effects on overall response rate and prolonged duration of responses observed in clinical trials across multiple indications. The product label includes warnings for various adverse reactions such as hepatotoxicity, hypertension, and embryo-fetal toxicity.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Editorial Material Oncology

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA

C. M. Della Corte et al.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Janice Kim et al.

Summary: The FDA granted accelerated approval for pralsetinib for non-small cell lung cancer and thyroid cancer, based on substantial overall response rates and durable responses in patients with RET-altered tumors. However, the product label includes warnings and precautions for various adverse events and risks.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Pathology

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas

Angela Chou et al.

MODERN PATHOLOGY (2020)

添加到收藏夹

Review Oncology

REToma: a cancer subtype with a shared driver oncogene

Takashi Kohno et al.

CARCINOGENESIS (2020)

添加到收藏夹

Article Oncology

Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development

Anthony W-H Chan et al.

JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurelien Marabelle et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

KIFSB-RET fusion gene and its correlation with clinicopathological and prognostic features in lung cancer: a meta-analysis

Xiao-Feng Cong et al.

ONCOTARGETS AND THERAPY (2019)

添加到收藏夹

Article Oncology

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

F. Pietrantonio et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients

Ari Vanderwalde et al.

CANCER MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

RET rearrangements are actionable alterations in breast cancer

Bhavna S. Paratala et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Oncology

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance

Alison M. Schram et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

Evgeny Yakirevich et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Oncology

ALKoma: A Cancer Subtype with a Shared Target

Hiroyuki Mano

CANCER DISCOVERY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma

C. Max Schmidt et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Large-scale analysis of the human and mouse transcriptomes

AI Su et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)

添加到收藏夹

Review Multidisciplinary Sciences

Oncogenic kinase signalling

P Blume-Jensen et al.

NATURE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.